Context.-Measured plasma or serum creatinine concentration is a primary component of equations used to calculate estimated glomerular filtration rate (eGFR). In recent years, most assay manufacturers have adopted creatinine calibration procedures that are traceable to the National Institute of Standards and Technology's Standard Reference Material 967.
Results.-Biases among current creatinine methods are in the range of À5% to 10%, compared with À7% to 34% seen in a 2003 study. This degree of bias in eGFR calculations is of clinical significance only for concentrations near the cut points used to stage chronic kidney disease. Approximately 20% of laboratories report eGFR values that exceed 61 mL/min per 1.73 m 2 from the expected eGFR using the 4-parameter Modification of Diet in Renal Disease equation.
Conclusions.-Since 2003, there have been improvements in the performance of creatinine assays, which appear to be related to the adoption of standard reference materials for calibration. The effect of the observed method biases in clinical practice now appears minimal. Laboratories should continue to monitor the accuracy of eGFR calculations.
(Arch Pathol Lab Med. 2013;137:496-502; doi: 10.5858/ arpa.2012-0134-CP) M easurement of plasma or serum creatinine is indicated for the assessment of renal function. That measurement is a primary component of the equations that provide estimated glomerular filtration rate (eGFR) to screening for and monitor chronic kidney disease (CKD). Routine reporting of eGFR by clinical laboratories has been recommended by several national organizations. 1, 2 Widespread implementation of the eGFR equations by clinical laboratories requires harmonization of creatinine field methods because the equations are intended to be independent of the laboratory method used to measure creatinine. Harmonization across test methods requires that systematic differences among methods and instruments be minimized so the same result, within clinically acceptable limits, is obtained for patient samples containing the same concentration of the constituent being measured.
In 2003, the College of American Pathologists (CAP) included a proficiency testing challenge (sample C-02) in the Chemistry C-Survey, which was composed of pooled, fresh-frozen, off-the-clot serum. 3, 4 The concentrations of 15 analytes in C-02 were measured by reference method procedures. The values assigned by the reference method procedures for creatinine was 0.902 mg/dL, measured by liquid-chromatography isotope-dilution mass spectrometry (IDMS). This proficiency testing material was considered to be free of biases arising from matrix effects and, therefore, suitable for comparing the performance of field methods and instruments among the 5624 participating laboratories in the C-Survey. For creatinine, observed biases from the values assigned by the reference method procedures ranged from À0.06 mg/dL to 0.31 mg/dL. Thirty peer groups (60% of all peer groups) were found to have significant biases in creatinine measurement from the reference method procedures value. Analysis of variance indicated that biases were attributable to manufacturers' instruments, rather than analytical principle, and, therefore, presumably arose from calibration differences among manufacturers.
Standards and Technology (NIST, Gaithersburg, Maryland), NIST SRM 967, used for method calibration by most manufacturers. 5 As of 2011, all but one major manufacturer of commercial creatinine assays had switched calibration traceability to the NIST SRM 967 material. Since 2005, the CAP has offered an accuracy-based serum creatinine product, the LN24 Creatinine Accuracy Calibration Verification/Linearity Survey, which has recently included an eGFR calculation challenge. Using results from the LN24 Creatinine Accuracy Survey, this study assesses the current state of standardization for creatinine field methods after adoption of calibration standards that are traceable to SRM 967 and examines changes in the performance of creatinine field methods since the 2003 CAP C-Survey challenge. Additionally, this study summarizes the results of laboratory-reported eGFR calculations.
MATERIALS AND METHODS
The CAP LN24 Creatinine Accuracy Calibration Verification/ Linearity Survey currently has an enrollment of more than 330 participants and includes laboratories that use a variety of commercial creatinine assays. The LN24 Survey contains multiple human serum samples, prepared according to a modification of the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) C37-A guideline. 6 Blood is collected from donors by venipuncture into plastic blood bags containing no anticoagulants or additives. Before 2007, the donors included only women; currently, the donors include an equal number of men and women. Blood bags are chilled during collection by immersion in an ice-water bath. Within 15 minutes of collection, the bags are centrifuged at 1500g for 8 minutes at 48C to separate plasma, which is transferred to a new plastic bottle and allowed to clot at 348C for 4 hours. Serum is collected by centrifugation and individual units are stored at À708C within 8 hours of collection. A low master pool is prepared by thawing the frozen units and gently mixing for at least 8 hours at 48C under argon to minimize oxidation. An aliquot of this material is spiked with crystalline creatinine (American Chemical Society, Charlotte, North Carolina, reagent grade) to make a high master pool with a target creatinine concentration of approximately 4.0 mg/L. Both master pools are filtered using 0.22-lm membranes. Admixtures of the low and high pools are prepared gravimetrically to make the intermediate concentration samples for the survey. Current lots contain 6 equally spaced admixtures of the low and high pools. The first lot, used before 2007, contained 7 samples. After preparation, samples are aliquoted into vials at 48C, which are then frozen at À708C before overnight shipping on ice packs to survey participants. Participants are instructed to thaw the survey samples and to mix by inverting the vials 4 to 5 times before measurement of creatinine.
For each lot of material, final concentrations of creatinine in selected samples are measured by liquid-chromatography isotopedilution mass spectrometry at NIST. Concentrations of creatinine in the other samples are calculated from admixture ratios. Samples prepared using this protocol for the LN24 survey and the SRM 967 reference material have been previously shown to be commutable to native, human serum samples with many common instrument and reagent systems. 7 Creatinine results in the LN24 Creatinine Accuracy Survey are evaluated using target values derived from NIST measurements and the admixture ratios from the manufacturing protocol. Although this study characterizes performance by instrument and method, peer means are not used in the LN24 calibration verification evaluation.
Effect of Analytical Bias on eGFR Calculation
Because creatinine is used for eGFR calculations in most laboratories, we examined the effect of creatinine assay performance on the eGFR in a hypothetical, clinical scenario of a 50-year-old, non-African American woman. We selected samples consistent with stage 3 CKD and calculated an eGFR from the participant results for this hypothetical patient using the 4-parameter Modification of Diet in Renal Disease (MDRD) equation. 8 We present these results to show the effect that standardization of creatinine measurements has had on eGFR. 
Accuracy of eGFR Calculations by Participating Laboratories
In the current LN24 Survey, we ask participating laboratories to provide an eGFR for 2 survey samples. Participants are provided with simulated age, ethnic group, and sex for calculation of the eGFR. We compare the reported eGFR values to expected values calculated using the 4-parameter MDRD equation, defining an acceptable participant result to be within 61 mL/min per 1. 
Statistical Analysis
The survey participant results were screened for outliers before the calculation of summary statistics and formal statistical analyses. Outliers were identified by visual inspection, and the calculation of thresholds was based on multiples of 3 standard deviations (3-SD test). To accommodate deviations from the Gaussian model, the 3-SD test included use of the median absolute deviation, as a robustscale estimate. Bias between survey results and assigned target values was calculated for selected peer groups. The statistical significance of absolute bias between the assigned target values and the mean for each group was assessed using one-sample, 2-sided t tests. Data were analyzed using SAS for Windows, version 8.2 software (SAS Inc., Cary, North Carolina) and S-PLUS 6.2 (TIBCO Software Inc., Palo Alto, California).
RESULTS

Observed Biases at Different Concentrations
Data on the performance of creatinine methods in LN24 surveys from 2005 through early 2011 are shown in Table 1 for low, midrange, and high sample results. Each lot of material spans 2 or 3 years, so we have selected samples with similar values across the full period, where possible. The percentage biases across peer groups from the target value has varied from À5% to þ10% across the 3 concentrations shown, 0.77 mg/dL, 2.75 mg/dL, and 4.04 mg/dL (actual concentrations varied slightly from lot to lot of the survey material). The 
Comparison of Creatinine Measurements Between 2003 and 2011
The biases observed among peer groups in samples C-02 of the 2003 C-Survey and LN24-01 of the 2011 LN24-A Survey were compared. These 2 samples have similar concentrations of creatinine representing normal donors (reference method procedure-measured creatinine concentrations of 0.902 mg/dL and 0.794 mg/dL, respectively). The results of this comparison are show in Table 2 .
Effect of Analytical Bias on eGFR Calculation
Using the 4-parameter MDRD equation, we compared the eGFR calculated from creatinine values obtained by various field methods between 2006 and 2011. This comparison was done using samples that had similar concentrations of creatinine (1.394 mg/dL and 1.435 mg/dL, respectively) ( Table 3 ). All the eGFRs agree within 2 mL/min per 1.73 m 2 (2011) or 3 mL/min per 1.73 m 2 (2006) of the eGFR using the NIST-assigned value. These differences would not result in a misclassification of this patient as being in something other than stage 3 CKD.
Accuracy of eGFR Calculations by Participating Laboratories
In recent LN24 Surveys, participants have been asked to report calculated eGFRs for samples with simulated age, sex, and race data. Table 4 summarizes the laboratories' performance for 2 samples in the LN24 2011A Survey. For each participant, we calculated the eGFR using the 4-parameter MDRD equation and the laboratory's reported creatinine. Calculations of eGFR within 61 mL/min per 1.73 m 2 were deemed acceptable. Table 4 shows the number and percentage of laboratories that reported eGFRs within the acceptable range (IDMS and Traditional refer to the MDRD equation used by the laboratory).
Our first challenge was simulated to be from a 50-yearold non-African American woman with an approximate creatinine value of 1.4 mg/dL. If the laboratory determined the creatinine to be 1.44 mg/dL (the NIST-assigned value) using an IDMS-traceable method, the eGFR would be 39 mL/min per 1.73 m 2 . Our second challenge was reported to be from a 25-yearold African American man with an approximate creatinine value of 2.1 mg/dL. If the laboratory determined the creatinine to be 2.10 mg/dL using an IDMS-traceable method, the eGFR would be 47 mL/min per 1.73 m 2 . To understand the potential reasons for miscalculation of the eGFR by participating laboratories, we modeled the expected eGFR calculations using the following possible sources of error: (1) use of traditional equation when IDMS claimed (and vice versa), (2) use of incorrect age, (3) use of incorrect sex, (4) use of incorrect race, (5) use of the CKD Epidemiology Collaboration equation instead of the MDRD equation; and (6) rounding errors. Table 5 shows the frequency of each possible error, or combination of errors.
COMMENT
Practice guidelines that include a patient's creatininebased eGFR for screening for, monitoring of, and progression of CKD have been advocated by several national organizations, including the National Kidney Disease Education Program (Bethesda, Maryland) and the National Kidney Foundation (New York, New York).
1,2 The most widely used method of estimating the GFR in US laboratories is the 4-parameter MDRD equation. [8] [9] [10] A more-recent equation, the CKD Epidemiology Collaboration equation, is currently less widely used but shows better agreement with measured GFR in patients with stage 1 and 2 CKD (ie, normal to mildly impaired GFR). 11 Both of these equations, the Cockcroft-Gault equation, 12 and the modified Schwartz equation, 13 which is used for children, incorporate plasma or serum creatinine measurements. The implementation of these and other eGFR equations is intended to be independent of the laboratory method used to measure creatinine. Standardization of creatinine methods and calibration are therefore essential to provide consistent eGFR results from different laboratories.
By comparison with the MDRD equation, the CockcroftGault equation tends to overestimate GFR. Moreover, the latter equation, which was developed in 1976, has not been reexpressed following recalibration of assay methods with IDMS-traceable creatinine standards, and the creatinine assay method that was used to derive the equation is no longer available. Its continued use, even for purposes of dosing drugs, is not recommended.
14 By contrast, the Schwartz equation has been reexpressed because of changes in creatinine calibration and is recommended for use in children. 13 All estimating equations are intended to be used for patients with stable renal function. In patients with rapidly changing renal function or in populations in which GFR estimating equations have not been validated, a formal measurement of GFR may be necessary. Cystatin C has been proposed as an alternative useful marker for estimating GFR, without the influence of muscle mass, age, or sex as confounding factors, although recent data indicate that cystatin C levels are influenced by factors other than the GFR alone. 15 The usefulness of cystatin C in identifying and monitoring progression of CKD does not appear to be markedly superior to that of creatinine.
Significant biases in creatinine calibration among several instrument/reagent groups were observed in the CAP's CSurvey in 2003, which incorporated a single, matrix-free, fresh-frozen serum challenge. 3 In that study, the mean bias for 50 peer groups per instrument method varied from À0.06 mg/dL to 0.31 mg/dL for a sample with a creatinine concentration of 0.902 mg/dL (ie, À7% to 34%). Since 2003, there have been extensive efforts to standardize creatinine field methods, including the use by instrument manufacturers of a NIST creatinine standard reference material, SRM 967. 5 The present study was intended to assess the current state of accuracy of creatinine assays and to observe trends in assay accuracy from the 2003 study.
The data in this study show that, since 2003, there has been an improvement in overall accuracy of creatinine methods. Observed biases in all methods and, in particular, in the most commonly used methods among laboratories in the LN24 survey, are in the range of À5% to þ10% of true creatinine concentrations. In the 2003 study, one instrument had a 34% bias, whereas the greatest instrument bias in 2011 was 7%. The largest 2003 bias for instruments in use in both 2003 and 2011 was 18%. The bias for that instrument was reduced to 4% in 2011, possibly due in part to a change in method principle. Based on analysis of eGFR calculations from a hypothetical 50-year-old non-African American patient with an eGFR of 39 to 40 mL/min per 1.73 m 2 , the creatinine biases observed among the instruments shown in Table 3 would give an absolute difference of the eGFR of not more than 2 to 3 mL/min per 1.73 m 2 from the NIST-assigned reference value. These biases would almost certainly not have clinical significance for this patient's care. More generally, differences of these sizes would result in different CKD classifications only for patients who have an eGFR that is around the cutoff value between 2 CKD stages. In the case of children, the eGFR calculated from the modified Schwartz equation 13 is inversely related to the measured creatinine concentration: eGFR (mL/min per 1.73 m 2 ) ¼ (0.41 3 height in cm)/(creatinine in mg/dL). A bias in the range of À5% to þ10% in creatinine measurement will result in a bias of approximately the same magnitude (but in the opposite direction) in eGFR when calculated using the modified Schwartz equation.
Because creatinine results are usually reported with an eGFR, this calculation must be performed correctly. The data from the 2011 A mailing show that 20% of laboratories are reporting values that are more than 61 mL/min per 1.73 m 2 from the value that would be obtained if the calculation were correctly performed using the MDRD equation. This is of concern because it is the eGFR and not simply the creatinine value that is used by clinicians in assessing the risk of CKD or assigning a patient to a stage of CKD. Efforts should be directed toward improving this calculation in clinical laboratories. Particular attention should be paid to the use of the appropriate equation and correct demographic information.
A limitation of this study is that the number of participants was significantly less than it was in the 2003 study, which is a reflection of the relative number of participants in the LN24 Survey compared with the Chemistry C Survey. A second possible limitation is that LN24 participants tend to be larger clinical laboratories that have chosen to participate in the Calibration Verification and Linearity Survey, which, unlike the C Survey, is not required for proficiency testing purposes. The performance of these laboratories may not be indicative of the performance of all clinical laboratories that perform creatinine measurements.
Despite these limitations, creatinine assays have improved in recent years, most likely because of improvements in calibration using IDMS-traceable creatinine calibration. The accuracy of methods is such that clinical misclassification of patients into the wrong CKD stage is only likely to occur around cutoff points between stages. Attention needs to be paid to accuracy of laboratory calculations of eGFR.
